<!DOCTYPE html><html lang="en"><head><meta charset="UTF-8"><meta name="viewport" content="width=device-width,initial-scale=1.0"><title>Kidney Health — SugarWise</title><link rel="stylesheet" href="styles.css"></head><body>
<nav class="navbar"><div class="navbar-inner"><a class="brand" href="index.html">SugarWise</a><a class="home-link" href="index.html">All Topics</a></div></nav>
<div class="container">
<div class="page-header"><h1>Kidney Health &amp; Diabetic Nephropathy</h1><p>Diabetes is the leading cause of chronic kidney disease and end-stage renal disease worldwide. Early detection and intervention can dramatically slow progression.</p></div>

<div class="illus">
<svg width="200" height="130" viewBox="0 0 200 130" fill="none" xmlns="http://www.w3.org/2000/svg">
<ellipse cx="100" cy="122" rx="55" ry="6" fill="#e2e8f0"/>
<!-- left kidney -->
<ellipse cx="65" cy="60" rx="28" ry="40" fill="#e53e3e" opacity="0.7" transform="rotate(-10 65 60)"/>
<ellipse cx="65" cy="60" rx="20" ry="30" fill="#c53030" opacity="0.5" transform="rotate(-10 65 60)"/>
<ellipse cx="70" cy="60" rx="6" ry="15" fill="#e53e3e" opacity="0.3"/>
<!-- right kidney -->
<ellipse cx="135" cy="60" rx="28" ry="40" fill="#e53e3e" opacity="0.7" transform="rotate(10 135 60)"/>
<ellipse cx="135" cy="60" rx="20" ry="30" fill="#c53030" opacity="0.5" transform="rotate(10 135 60)"/>
<ellipse cx="130" cy="60" rx="6" ry="15" fill="#e53e3e" opacity="0.3"/>
<!-- connecting ureter lines -->
<path d="M75 90 Q100 110 100 120" stroke="#c53030" stroke-width="3" fill="none"/>
<path d="M125 90 Q100 110 100 120" stroke="#c53030" stroke-width="3" fill="none"/>
<!-- pulse -->
<circle cx="65" cy="55" r="5" fill="#fff" opacity="0.4"><animate attributeName="r" values="3;8;3" dur="2s" repeatCount="indefinite"/><animate attributeName="opacity" values="0.5;0.1;0.5" dur="2s" repeatCount="indefinite"/></circle>
<circle cx="135" cy="55" r="5" fill="#fff" opacity="0.4"><animate attributeName="r" values="3;8;3" dur="2s" repeatCount="indefinite" begin="0.5s"/><animate attributeName="opacity" values="0.5;0.1;0.5" dur="2s" repeatCount="indefinite" begin="0.5s"/></circle>
</svg>
</div>

<div class="section">
<h2><span class="icon-sm">&#129516;</span> How Diabetes Damages the Kidneys</h2>
<p>The kidneys filter approximately 180 liters of blood daily through millions of tiny filtering units called glomeruli. Chronic hyperglycemia damages these delicate structures by causing glomerular hypertrophy, basement membrane thickening, mesangial expansion, and eventually glomerulosclerosis (scarring). Hypertension further accelerates damage by increasing intraglomerular pressure.</p>
<p>Diabetic kidney disease (DKD) affects 20-40% of people with diabetes and typically develops over 10-20 years, though progression varies widely between individuals.</p>
</div>

<div class="section">
<h2><span class="icon-sm">&#128200;</span> Stages of Diabetic Nephropathy</h2>
<div class="table-wrap">
<table>
<thead>
<tr><th>Stage</th><th>Description</th><th>UACR (mg/g)</th><th>eGFR (mL/min/1.73m²)</th><th>Clinical Features</th></tr>
</thead>
<tbody>
<tr><td>1 — Hyperfiltration</td><td>Kidney works overtime; enlarged kidneys</td><td>Normal (&lt;30)</td><td>&gt;90 (often elevated)</td><td>No symptoms; may be reversible with glucose control</td></tr>
<tr><td>2 — Silent</td><td>Structural changes begin (basement membrane thickening)</td><td>Normal (&lt;30)</td><td>&gt;90</td><td>No symptoms; detectable only on biopsy</td></tr>
<tr><td>3 — Microalbuminuria</td><td>Small amounts of albumin leak into urine</td><td>30-300</td><td>May begin to decline</td><td>First detectable sign; still reversible with aggressive treatment</td></tr>
<tr><td>4 — Macroalbuminuria</td><td>Large amounts of protein in urine</td><td>&gt;300</td><td>Declining</td><td>Hypertension worsens; edema may develop; progressive decline likely</td></tr>
<tr><td>5 — ESRD</td><td>End-stage renal disease; kidneys fail</td><td>Variable</td><td>&lt;15</td><td>Requires dialysis or kidney transplant; uremic symptoms</td></tr>
</tbody>
</table>
</div>
<div class="note">Not everyone follows this classic linear progression. Some patients develop reduced eGFR without significant albuminuria (non-albuminuric DKD), which is increasingly recognized, especially in Type 2 diabetes.</div>
<div class="timeline">
<div class="timeline-item"><div class="timeline-title">Stage 1 &mdash; Hyperfiltration</div><div class="timeline-text">Kidneys overwork; reversible with good glucose control</div></div>
<div class="timeline-item"><div class="timeline-title">Stage 2 &mdash; Silent Damage</div><div class="timeline-text">Structural changes begin; no symptoms, detectable only on biopsy</div></div>
<div class="timeline-item"><div class="timeline-title">Stage 3 &mdash; Microalbuminuria</div><div class="timeline-text">First detectable sign; still reversible with aggressive treatment</div></div>
<div class="timeline-item"><div class="timeline-title">Stage 4 &mdash; Macroalbuminuria</div><div class="timeline-text">Heavy protein loss; progressive decline likely; edema develops</div></div>
<div class="timeline-item"><div class="timeline-title">Stage 5 &mdash; ESRD</div><div class="timeline-text">Kidney failure; requires dialysis or transplant</div></div>
</div>
</div>

<div class="section">
<h2><span class="icon-sm">&#128269;</span> Screening for Diabetic Kidney Disease</h2>
<ul>
<li><strong>Urine albumin-to-creatinine ratio (UACR):</strong> Measured from a random spot urine sample. Abnormal if ≥30 mg/g. Confirm with 2 of 3 samples over 3-6 months (transient elevations can occur with exercise, fever, UTI, or heart failure).</li>
<li><strong>Estimated glomerular filtration rate (eGFR):</strong> Calculated from serum creatinine (and optionally cystatin C). Normal is ≥90; &lt;60 indicates CKD stage 3 or worse.</li>
<li><strong>Frequency:</strong> Annually for all people with Type 2 diabetes starting at diagnosis, and for Type 1 diabetes starting 5 years after diagnosis.</li>
<li><strong>Both tests together:</strong> UACR and eGFR should always be assessed together, as either can be abnormal independently.</li>
</ul>
<div class="table-wrap">
<table>
<thead>
<tr><th>CKD Stage</th><th>eGFR Range</th><th>Action</th></tr>
</thead>
<tbody>
<tr><td>G1</td><td>≥90</td><td>Monitor; treat risk factors</td></tr>
<tr><td>G2</td><td>60-89</td><td>Monitor; treat risk factors</td></tr>
<tr><td>G3a</td><td>45-59</td><td>Increase monitoring frequency; adjust medications; consider nephrology referral</td></tr>
<tr><td>G3b</td><td>30-44</td><td>Nephrology referral; medication dose adjustments; monitor for complications</td></tr>
<tr><td>G4</td><td>15-29</td><td>Nephrology co-management; prepare for renal replacement therapy</td></tr>
<tr><td>G5</td><td>&lt;15</td><td>Dialysis or transplant evaluation</td></tr>
</tbody>
</table>
</div>
</div>

<div class="section">
<h2><span class="icon-sm">&#128737;</span> Prevention and Treatment</h2>
<h3>Blood Pressure Control</h3>
<ul>
<li>Target &lt;130/80 mmHg (some guidelines suggest &lt;125/75 if significant proteinuria).</li>
<li><strong>ACE inhibitors or ARBs</strong> are the cornerstone — they reduce intraglomerular pressure and slow albuminuria progression independent of their blood pressure effect.</li>
<li>Start an ACE inhibitor or ARB at the first sign of persistently elevated UACR (≥30 mg/g), even if blood pressure is normal.</li>
<li>Monitor creatinine and potassium 1-2 weeks after starting or titrating.</li>
<li>A rise in creatinine of up to 30% is acceptable after starting ACEi/ARB and reflects reduced hyperfiltration.</li>
</ul>

<h3>SGLT2 Inhibitors</h3>
<ul>
<li>Dapagliflozin, canagliflozin, and empagliflozin have demonstrated significant renal protection in major trials (CREDENCE, DAPA-CKD, EMPA-KIDNEY).</li>
<li>Reduce the risk of CKD progression, ESRD, and renal death by 30-40%.</li>
<li>Benefits are additive to ACEi/ARB therapy.</li>
<li>Can be used down to eGFR 20-25 mL/min (check specific agent labeling).</li>
<li>Now recommended by KDIGO and ADA guidelines for all people with Type 2 diabetes and CKD.</li>
</ul>

<h3>Glycemic Control</h3>
<ul>
<li>Target HbA1c &lt;7% for most (individualize based on CKD stage, hypoglycemia risk, and life expectancy).</li>
<li>Metformin: safe down to eGFR 30; reduce dose at eGFR 30-45; stop below 30.</li>
<li>Insulin: may require dose reduction as kidney function declines (kidneys clear ~30% of insulin).</li>
<li>Sulfonylureas: avoid glibenclamide/glyburide in CKD (active metabolites accumulate); glipizide is preferred if needed.</li>
<li>GLP-1 RAs: generally safe; some require dose adjustment in severe CKD.</li>
</ul>

<h3>Finerenone (Non-Steroidal MRA)</h3>
<ul>
<li>A newer agent shown in FIDELIO-DKD and FIGARO-DKD trials to reduce CKD progression and cardiovascular events in diabetic kidney disease.</li>
<li>Added on top of maximally tolerated ACEi/ARB.</li>
<li>Monitor potassium closely (risk of hyperkalemia).</li>
</ul>
</div>

<div class="section">
<h2><span class="icon-sm">&#127860;</span> Dietary Protein Recommendations</h2>
<ul>
<li><strong>Early CKD (stages 1-2):</strong> No strict protein restriction needed. Aim for ~0.8 g/kg/day (the general recommended dietary allowance).</li>
<li><strong>Moderate-advanced CKD (stages 3-5, not on dialysis):</strong> 0.8 g/kg/day; some guidelines suggest 0.6-0.8 g/kg/day to reduce uremic toxin production.</li>
<li><strong>On dialysis:</strong> Higher protein intake needed (1.0-1.2 g/kg/day) to compensate for dialysis losses.</li>
<li>Prioritize high-quality protein sources (eggs, fish, poultry, dairy).</li>
<li>Work with a renal dietitian for individualized meal planning.</li>
</ul>
<div class="tip">Beyond protein, people with CKD may also need to limit sodium (&lt;2 g/day), potassium, and phosphorus as kidney function declines. A renal dietitian is an essential member of your care team.</div>
</div>

<div class="section">
<h2><span class="icon-sm">&#128204;</span> Other Important Considerations</h2>
<ul>
<li><strong>Avoid nephrotoxins:</strong> NSAIDs (ibuprofen, naproxen), certain antibiotics (aminoglycosides), and IV contrast dye can worsen kidney function. Always inform providers about your CKD status.</li>
<li><strong>Anemia:</strong> The kidneys produce erythropoietin. As CKD progresses, anemia develops. Monitor hemoglobin; treat with iron supplementation and/or erythropoiesis-stimulating agents (ESAs) as needed.</li>
<li><strong>Bone health:</strong> CKD disrupts calcium-phosphorus-vitamin D metabolism (CKD-MBD). Monitor calcium, phosphorus, PTH, and vitamin D levels.</li>
<li><strong>Cardiovascular risk:</strong> CKD dramatically amplifies cardiovascular risk. Most people with CKD stage 3+ are more likely to die from CVD than to reach dialysis.</li>
</ul>
</div>

<div class="section">
<h2><span class="icon-sm">&#129658;</span> When to See a Nephrologist</h2>
<ul>
<li>eGFR &lt;30 mL/min/1.73m² (CKD stage 4-5).</li>
<li>Persistent significant albuminuria (UACR &gt;300 mg/g).</li>
<li>Rapid decline in eGFR (&gt;5 mL/min/year or &gt;25% decline over 3 months).</li>
<li>Difficult-to-manage hypertension despite 3+ medications.</li>
<li>Persistent hyperkalemia or metabolic acidosis.</li>
<li>Suspected non-diabetic kidney disease (hematuria, nephrotic-range proteinuria without retinopathy, rapid onset).</li>
</ul>
</div>

<div class="section">
<h2><span class="icon-sm">&#127981;</span> Dialysis and Transplant</h2>
<p>When the kidneys can no longer sustain life (eGFR &lt;10-15), renal replacement therapy is required:</p>
<ul>
<li><strong>Hemodialysis:</strong> Blood is filtered through a machine, typically 3 times/week for 3-4 hours. Requires a vascular access (fistula preferred, created 6+ months ahead).</li>
<li><strong>Peritoneal dialysis:</strong> Uses the peritoneal membrane as a natural filter; fluid is exchanged through an abdominal catheter. Can be done at home.</li>
<li><strong>Kidney transplant:</strong> The preferred treatment for eligible patients. Offers better survival and quality of life than dialysis. Pre-emptive transplant (before dialysis) gives the best outcomes. Living donor transplants have superior graft survival.</li>
</ul>
<div class="warning">Plan ahead. Discuss renal replacement options early (at eGFR ~20-25) so that access can be created, transplant evaluation can begin, and you can make informed decisions without the pressure of an emergency start.</div>
</div>

<div class="page-nav">
<a class="prev" href="heart-health.html">Heart Health</a>
<a class="next" href="eye-health.html">Eye Health</a>
</div>
</div>
<div class="disclaimer">This content is for educational purposes only and does not replace professional medical advice. The creators of SugarWise are not medical professionals. Do not start, stop, or change any medication without consulting your doctor. In case of emergency, call 112 (India) or your local emergency number. <a href="terms-of-use.html">Read full Terms of Use &amp; Medical Disclaimer</a></div>
<div class="footer">SugarWise &bull; Comprehensive Diabetes Management Companion &bull; <a href="terms-of-use.html">Terms of Use</a> &bull; Last updated: January 2026</div>
<button class="scroll-top" id="scrollTop" title="Back to top">&uarr;</button>
<script>
var sb=document.getElementById('scrollTop');window.addEventListener('scroll',function(){sb.classList.toggle('visible',window.scrollY>400)});sb.addEventListener('click',function(){window.scrollTo({top:0,behavior:'smooth'})});
</script>
</body></html>